Bafna Pharmaceuticals, a Chennai-based pharma company engaged in the manufacturing of pharmaceutical formulations of betalactum and non–betalactum, received approval from Ghana Food and Drug Administration (FDA) to market atenolol 50 mg and atenolol 100 mg tablets, a hypertension drug. Following this development, it is the 9th formulation approval received from Ghana FDA for a product by Bafna Pharmaceuticals Ltd.

Atenolol is a selective ß1 receptor antagonist, a drug belonging to the group of beta blockers, a class of drugs used primarily in cardiovascular diseases. Atenolol can be used to treat cardiovascular diseases and conditions such as hypertension, coronary heart disease, arrhythmias, angina (chest pain) and to treat and reduce the risk of heart complications following myocardial infarction (heart attack). It is also used to treat the symptoms of Graves Disease, until antithyroid medication can take effect.

According to a press release, Bafna Pharma had earlier received product approval from Ghana FDA, which includes metformin tablets BP 500mg, fluconazole tablets 150 mg, iron tonic fortified with protein, folic acid, vitamin B12 and zinc syrup, haematinic capsules with vitamins and zinc, azithromycin tablets 250mg, azithromycin tablets 500 mg, amlodipine besilate tablets 5mg and amlodipine besilate tablets 10 mg.

Commenting on the approval, Mahaveer Chand Bafna, chairman and MD of Bafna Pharmaceuticals, said, “We are extremely pleased to receive FDA approval to market atenolol tablets 50 mg and 100 mg tablets. It offers an important additional treatment option for physicians and hypertension patients. Following the recent approvals from the FDA in Ghana, Bafna Pharma will be able to widen its customer base in the region.”